Brought to you by 
Celltech merges with Chiroscience in $535mm all-stock deal
02 Feb 2000
Executive Summary
Celltech PLC will merge with Chiroscience Group PLC in a $535mm (UK331mm) all-stock transaction of 70.1mm shares. Celltech Chiroscience will have a dozen drugs in its pipeline, seven of them at least in Phase II, and an estimated market value of $1.1bn (UK684mm).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celltech merges with Chiroscience in $535mm all-stock deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice